Pacira BioSciences Inc. reported increased total revenue and net product sales in its first-quarter 2022 financial results, according to a press release.
The company reported a net income of $6.8 million and a total revenue of $158 million, an increase of 33% from the prior year period. Net product sales were $129.2 million for Exparel, $23.6 million for Zilretta and $3 million for Iovera, according to the release.
“We were delighted to end the first quarter of 2022 with record-high Exparel sales for the month of March, which underscores the significant progress we continue to make